NY-ESO-1 peptide–HLA-A*02:01 complex

The NY-ESO-1/HLA-A*02:01 complex consists of a peptide epitope, most commonly the nonamer SLLMWITQC (NY-ESO-1 residues 157–165), derived from the NY-ESO-1 (New York esophageal squamous cell carcinoma 1) cancer-testis antigen, bound within the peptide-binding groove of the human MHC class I molecule HLA-A*02:01. NY-ESO-1 is highly immunogenic and selectively expressed in a wide range of tumors but not in normal somatic tissues, making it a leading candidate for cancer immunotherapy. The complex is specifically recognized by cytotoxic T lymphocytes and has been targeted by adoptive T cell therapies and peptide vaccines in ongoing clinical trials. Its use is restricted to patients with the HLA-A*02:01 allele, and its pharmacological activity is mediated by TCR-guided immune attacks against NY-ESO-1–positive cancer cells. Structural biology has enabled the design of optimized peptides and analogues for improved immunogenicity and therapeutic index.\nIf more precise details on sequence, structure, or clinical interventions are required, they can be tailored using this foundational information.

Other names

NY-ESO-1/HLA-A2 complexSLLMWITQC–HLA-A2 complexNY-ESO-1–derived epitope/HLA-A*02:01 complexNY-ESO-1_157-165 peptide/HLA-A*02:01

Recognition by engineered TCRs or T cells leads to selective lysis of NY-ESO-1–positive, HLA-A*02:01–positive tumor cells\nVaccines aimed at inducing cytotoxic T lymphocyte (CTL) and/or helper T cell responses toward NY-ESO-1/HLA-A*02:01–expressing tumor cells